Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2013

01-10-2013 | Original Article

Ultrasonographic Quantification of Hepatic–Renal Echogenicity Difference in Hepatic Steatosis Diagnosis

Authors: Jing-Houng Wang, Chao-Hung Hung, Fang-Ying Kuo, Hock-Liew Eng, Chien-Hung Chen, Chun-Mo Lee, Sheng-Nan Lu, Tsung-Hui Hu

Published in: Digestive Diseases and Sciences | Issue 10/2013

Login to get access

Abstract

Background and Aim

Ultrasound (US) is recommended for hepatic steatosis screening. The purpose of this study was to determine the usefulness of US hepatic-renal echo-intensity (HR) difference in the quantitative assessment of hepatic steatosis.

Methods

Consecutive patients undergoing liver biopsy were prospectively enrolled. Using US histogram technique, the mean gray level of hepatic parenchyma and right renal parenchyma at selected regions of interest were evaluated on the same day of biopsy. With steatosis assessed by histology as the reference, the diagnostic performances of HR difference in predicting the degree of steatosis was analyzed. The optimal cut-off level, diagnostic validity and post-test probability were assessed.

Results

A total of 175 patients were enrolled (M/F, 103/72; mean age, 48.6 ± 11.7). There were 64 (36.5 %), 42 (24 %), 29 (16.6 %), 12 (6.9 %) and 28 (16 %) patients with steatosis of <5, 5–9, 10–19, 20–29 and ≥30 %, respectively. Multivariate analysis showed HR difference correlated with the severity of steatosis (R 2 = 0.425, p < 0.001) with positive correlation between HR difference and the severity of steatosis (r = 0.60, p < 0.001). The diagnostic performances were 0.927, 0.890, 0.816 and 0.760 for steatosis ≥30, ≥20, ≥10 and ≥5 %, respectively. The cut-off is 7 for diagnosing steatosis ≥30 %, with a negative predictive value of 97.6 %. The cut-off is 4 in predicting steatosis ≥5 %, with a positive predictive value of 79 %. The prevalence of steatosis influenced the post-test probability.

Conclusions

Quantitative assessment of HR difference with US histogram technique is useful in excluding moderate to severe hepatic steatosis.
Literature
1.
go back to reference Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367.PubMed Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367.PubMed
2.
go back to reference Petta S, Camma C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver int. 2011;31:507–515.PubMedCrossRef Petta S, Camma C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver int. 2011;31:507–515.PubMedCrossRef
3.
go back to reference Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012;7:e34198.PubMedCrossRef Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012;7:e34198.PubMedCrossRef
4.
go back to reference Ates F, Yalniz M, Alan S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol. 2011;17:4517–4522.PubMedCrossRef Ates F, Yalniz M, Alan S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol. 2011;17:4517–4522.PubMedCrossRef
5.
go back to reference Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes. 2007;31:871–875. Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes. 2007;31:871–875.
6.
go back to reference Hung CH, Kuo FY, Wang JH, et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther. 2006;11:483–489.PubMed Hung CH, Kuo FY, Wang JH, et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther. 2006;11:483–489.PubMed
7.
go back to reference Negro F, Clement S. Impact of obesity, steatosis, and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat. 2009;16:681–688.PubMedCrossRef Negro F, Clement S. Impact of obesity, steatosis, and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat. 2009;16:681–688.PubMedCrossRef
8.
go back to reference Vernon G, Baranova A, Younossi ZM. Systemic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.PubMedCrossRef Vernon G, Baranova A, Younossi ZM. Systemic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.PubMedCrossRef
10.
go back to reference Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.PubMedCrossRef Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.PubMedCrossRef
11.
go back to reference Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481–486.PubMedCrossRef Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481–486.PubMedCrossRef
12.
go back to reference Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–445.PubMedCrossRef Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–445.PubMedCrossRef
13.
go back to reference Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090.PubMedCrossRef Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090.PubMedCrossRef
14.
go back to reference Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–777.PubMedCrossRef Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–777.PubMedCrossRef
15.
go back to reference Drost WT, Henry GA, Meinkoth JH, et al. Quantification of hepatic and renal cortical echogenicity in clinically normal cat. Am J Vet Res. 2000;61:1016–1020.PubMedCrossRef Drost WT, Henry GA, Meinkoth JH, et al. Quantification of hepatic and renal cortical echogenicity in clinically normal cat. Am J Vet Res. 2000;61:1016–1020.PubMedCrossRef
16.
go back to reference Schulman P. Bayes’ theorem—a review. Cardiol Clin. 1984;2:319–328.PubMed Schulman P. Bayes’ theorem—a review. Cardiol Clin. 1984;2:319–328.PubMed
17.
go back to reference Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384.PubMedCrossRef Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384.PubMedCrossRef
18.
go back to reference Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54:700–713.PubMedCrossRef Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54:700–713.PubMedCrossRef
19.
go back to reference Perez NE, Siddiqui FA, Mutchunick MG, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease—a retrospective observational study. J Clin Gastroenterol. 2007;41:624–629.PubMedCrossRef Perez NE, Siddiqui FA, Mutchunick MG, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease—a retrospective observational study. J Clin Gastroenterol. 2007;41:624–629.PubMedCrossRef
20.
go back to reference Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational stuffy. BMC Gastroenterol. 2005;5:14.PubMedCrossRef Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational stuffy. BMC Gastroenterol. 2005;5:14.PubMedCrossRef
21.
go back to reference Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism. 2009;58:1724–1730.PubMedCrossRef Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism. 2009;58:1724–1730.PubMedCrossRef
22.
go back to reference Xia MF, Yan HM, He WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity. 2012;20:444–452.PubMedCrossRef Xia MF, Yan HM, He WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity. 2012;20:444–452.PubMedCrossRef
23.
go back to reference Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol. 2009;192:909–914.CrossRef Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol. 2009;192:909–914.CrossRef
24.
go back to reference Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound. 1996;24:25–29.PubMedCrossRef Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound. 1996;24:25–29.PubMedCrossRef
25.
go back to reference Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21:87–97.PubMedCrossRef Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21:87–97.PubMedCrossRef
26.
go back to reference Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRef Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRef
27.
go back to reference Lonardo A, Ballestri S, Adinolfi LE, et al. Hepatitis C virus-infected patients are ‘spared’ from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol. 2009;23:273–278.PubMed Lonardo A, Ballestri S, Adinolfi LE, et al. Hepatitis C virus-infected patients are ‘spared’ from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol. 2009;23:273–278.PubMed
28.
go back to reference Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRef Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRef
29.
go back to reference Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.PubMedCrossRef Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.PubMedCrossRef
30.
go back to reference Stippel G, Philips W, Govaert P. A tissue-specific adaptive texture filter for medical ultrasound images. Ultrasound Med Biol. 2005;31:1211–1223.PubMedCrossRef Stippel G, Philips W, Govaert P. A tissue-specific adaptive texture filter for medical ultrasound images. Ultrasound Med Biol. 2005;31:1211–1223.PubMedCrossRef
Metadata
Title
Ultrasonographic Quantification of Hepatic–Renal Echogenicity Difference in Hepatic Steatosis Diagnosis
Authors
Jing-Houng Wang
Chao-Hung Hung
Fang-Ying Kuo
Hock-Liew Eng
Chien-Hung Chen
Chun-Mo Lee
Sheng-Nan Lu
Tsung-Hui Hu
Publication date
01-10-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2769-8

Other articles of this Issue 10/2013

Digestive Diseases and Sciences 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.